---
title: "Descartes-08 in Generalized myasthenia gravis: Access and distribution"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Access and distribution. Topics: Centralized in-house manufacture and lot release time of about three weeks, Manufacturing success: participants meeting manufacturing specifications in the phase 2b trial, Commercial infrastructure plans, and Community clinic administration as a design goal of the product. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/access-and-distribution"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Centralized in-house manufacture and lot release time of about three weeks

> “We manufacture Descartes-08 in-house and are typically able to process and release lots for infusion within approximately three weeks.”
> “We have optimized our manufacturing processes through over 200 cGMP runs across all of our current and prior programs.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “Typical lot processed for infusion within as little as ~3 weeks”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.1.2.11-2"></a>

### Manufacturing success: participants meeting manufacturing specifications in the phase 2b trial

> “Of the 45 patients who met the inclusion criteria, 36 were eligible to be randomized after meeting manufacturing specifications, of whom 20 were assigned to the active Descartes-08 arm, and 16 were assigned to the placebo arm.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.11-3"></a>

### Commercial infrastructure plans

> “We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products.”
> “We expect to build a focused sales and marketing infrastructure to market or co-promote our product candidates in the United States and potentially elsewhere, if and when they are approved.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “As we advance toward this next phase of growth, an extended cash runway into 2028, supported by up to $150 million of non-dilutive financing through a credit facility with K2 HealthVentures (“K2HV”), allows us to continue investing in precommercial readiness activities in parallel with clinical execution.”

Source: [Cartesian Therapeutics second quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-second-quarter-2026-financial)

<a id="topic-2.1.2.11-4"></a>

### Community clinic administration as a design goal of the product

> “To broaden use of CAR T-cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma.”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
